Pathologic Cancer Staging by Measuring Cell Growth Energy

摘要

The aim of this research is to establish a pathologic cancer staging by measuring Cell Growth Energy (CGE) contributes to treatment management and helps to administer the appropriate low-waste dose for all cancer therapies. Regarding cancer as a cell cycle disruption disease; Nitrogen-containing bisphosphonates (NBP) Alendronate (ALN) of different concentrations were added to samples of Normal Human Epidermal Keratinocytes (NHEKs) (20,000Cell /sample) to inhibit their growth rate to model cancer effects on normal cells, [~(14)C] thymidine was added at 0.5 μCi/ml to each of control sample and those of cell cycle arrest (with NBPs) to monitor the Cell Growth Energy (CGE) which expresses all aberrant activations of cell that lead to cancer development and simply describes the cancer stage of the cell. Radioactivity incorporated (% of control) at 37℃ was determined as a measure of cell rate of growth at 24-h intervals for 3 days using a Top Count NTX micro plate scintillation counter. NHEKs rate of growth for sample with NBP of concentration 10 μM ALN was the closest to that of induced carcinomas, equivalent to 87% of that of the normal counterpart as measured by [~(14)C ] thymidine incorporation (p<0.001). As inhibition to rate of growth of this sample was 13% compared to the control, cell doubling time was increased consequently to 1.13 times that of cells of the control sample. By equalizing growth energy of this sample to the energy of the induced inhibition to [~(14)C] thymidine incorporation, CGE gained due to cell cycle arrest was 4862 MeV =0.21 Emad. According to Emad formula the corresponding cell doubling time is 1.12 times that of cells at the stage of Natural Background Radiation. This is 99% identical to what has been measured experimentally at 1.13 times that of control cells to confirm and provide a clear-cut criterion for accepting the CGE test for cancer staging.